Back to search

Peptide record

TPDB11502

Antibacterial Toxicity standard
34 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB11502
Antibacterial Toxicity
Anti-infective peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia
standard
No
A 34-aa standard natural multi-activity (Antibacterial and Toxicity) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
KRFKKFFRKLKKSVKKRKKEFKKKPRVIKVSIPF
Physicochemical Analysis
C207H354N60O39
ANDCQGHMTWY
K
4307.47
12.47
18
1
11
+17
13.66
-1.221
60.00
Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min
0
0.00
2
Residue Composition
number
0
A
4
R
0
N
0
D
0
C
1
E
0
Q
0
G
0
H
2
I
1
L
14
K
0
M
5
F
2
P
2
S
0
T
0
W
0
Y
3
V
Amino Acid Distribution
A: 0 R: 4 N: 0 D: 0 C: 0 E: 1 Q: 0 G: 0 H: 0 I: 2 L: 1 K: 14 M: 0 F: 5 P: 2 S: 2 T: 0 W: 0 Y: 0 V: 3
Chemical Descriptors
34
C207H354N60O39
4307.47
12.47
+17
13.66
-1.221
Evidence Records 8 records
Evidence 1 Activity

Activity

MIC
Antibacterial
16 µg/mL

Target

Staphylococcus aureus ATCC 25923

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class. DRAMP antibacterial activity supported by MIC records against bacterial target organisms.
active against S. aureus ATCC 25923 (MIC 16 ug/ml), S.aureus ATCC 33591 (MIC 128 ug/ml) and 14 clinical strains (MIC 32-128 ug/ml), E. coli
Evidence 2 Activity

Activity

MIC
Antibacterial
128 µg/mL

Target

S.aureus ATCC 33591

Source & Reference

dbAMP DRAMP

Other

active against S. aureus ATCC 25923 (MIC 16 ug/ml), S.aureus ATCC 33591 (MIC 128 ug/ml) and 14 clinical strains (MIC 32-128 ug/ml), E. coli ATCC 25922 or ATCC 51446 (MIC 8-16 ug
Evidence 3 Activity

Activity

MIC
Antibacterial
8-16 µg/mL

Target

Escherichia coli ATCC 25922 or ATCC 51446

Source & Reference

dbAMP DRAMP

Other

6 ug/ml), S.aureus ATCC 33591 (MIC 128 ug/ml) and 14 clinical strains (MIC 32-128 ug/ml), E. coli ATCC 25922 or ATCC 51446 (MIC 8-16 ug/ml), K. pneumoniae ATCC 13883 or ATCC 700603 (MIC 16-64 ug/ml).
Evidence 4 Activity

Activity

MIC
Antibacterial
16-64 µg/mL

Target

Klebsiella pneumoniae ATCC 13883 or ATCC 700603

Source & Reference

dbAMP DRAMP

Other

4 clinical strains (MIC 32-128 ug/ml), E. coli ATCC 25922 or ATCC 51446 (MIC 8-16 ug/ml), K. pneumoniae ATCC 13883 or ATCC 700603 (MIC 16-64 ug/ml).
Evidence 5 Activity

Activity

22% Hemolysis
Toxicity
500 µg/mL
Hemolytic Cytotoxic
22% Hemolysis | 500 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
The antimicrobial potential of a new derivative of cathelicidin from Bungarus fasciatus against methicillin-resistant Staphylococcus aureus. | J Microbiol | 2018
Evidence 6 Activity

Activity

<5% Hemolysis
Toxicity
125 µg/mL
Hemolytic Cytotoxic
<5% Hemolysis | 125 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
The antimicrobial potential of a new derivative of cathelicidin from Bungarus fasciatus against methicillin-resistant Staphylococcus aureus. | J Microbiol | 2018
Evidence 7 Activity

Activity

20% Cell death
Toxicity
81 µg/mL
Cytotoxic
20% Cell death | 81 | µg/mL | target cell: Human umbilical vein endothelial cells HUVEC

Target

Human umbilical vein endothelial cells HUVEC

Source & Reference

NA
DBAASP
The antimicrobial potential of a new derivative of cathelicidin from Bungarus fasciatus against methicillin-resistant Staphylococcus aureus. | J Microbiol | 2018
Evidence 8 Activity

Activity

% Hemolysis
Toxicity
0 %
Hemolytic Cytotoxic
Hemolytic_activity: [Ref.29392557] 0% haemolysis at 1.0 µg/ml, 0% haemolysis at 2.0 µg/ml, 0% haemolysis at 4.0 µg/ml, 0% haemolysis at 8.0 µg/ml, 0% haemolysis at 16.0 µg/ml, 0% haemolysis at 31.2 µg/ml, 2% haemolysis at 62.5 µg/ml, 4% haemolysis at 125.0 µg/ml, 15% haemolysis at 250.0 µg/ml, 23% haemolysis at 500.0 µg/ml, 53% haemolysis at 1000.0 µg/ml against human red blood cells | Cytotoxicity: [Ref.29392557] The cell viability of HUVEC is 132%, 99% and 79% at peptide concentrations of 35.5, 71 and 113 µg/ml .## The cell viability of H9c2is 129%, 97%, and 80% at peptide concentrations of 35.5, 71, and 113 µg/ml .

Target

erythrocytes

Source & Reference

NA
DRAMP
J Microbiol. 2018 Feb 56(2):128-137.